Quick Facts

• Up to 40% of weight lost on GLP-1 drugs comes from muscle without proper intervention
• New GPS framework helps patients preserve muscle while losing fat on semaglutide and tirzepatide
• Medicare will cover GLP-1s for weight loss at $50 monthly starting July 2026

A new doctor-approved protocol addresses a hidden problem with GLP-1 weight loss drugs. Up to 40% of weight lost on medications like semaglutide and tirzepatide comes from lean muscle tissue, not fat.

Dr. Rocio Salas-Whalen created the GPS framework to help patients preserve muscle during GLP-1 therapy. The system focuses on three key areas: adequate protein intake, progressive strength training, and proper sleep.

Clinical studies show the muscle loss problem is significant. In the STEP-1 trial, patients lost 9.7% of lean mass while on semaglutide. For someone losing 15-20% of their body weight, that translates to 8-15 pounds of lost muscle.

Protein Requirements Drive Success

Salas-Whalen recommends one gram of protein per pound of ideal body weight. Women typically need 100 grams daily for maintenance and 120 grams for muscle building. Men require 140 grams for maintenance and up to 160 grams to build muscle.

Dr. Kevin Gendreau monitors patients with bloodwork at treatment start and six months later. This catches muscle loss early rather than waiting for symptoms to appear.

Breakthrough Combination Therapy

The BELIEVE trial tested bimagrumab combined with semaglutide. Results showed 22.1% body weight reduction with 92.8% of weight loss coming from fat mass. Lean muscle loss dropped to just 2.6% compared to 7.9% with semaglutide alone.

Preclinical studies found semaglutide alone reduced lean body mass by 10%. The combination therapy completely preserved muscle mass with no change from baseline.

Medicare Coverage Expansion

Starting July 1, 2026, Medicare beneficiaries can get GLP-1 prescriptions for weight loss at $50 monthly. The pilot program runs through December 31, 2027.

Eligibility requires BMI of 27 or higher plus conditions like heart disease or prediabetes. Patients with BMI 35 or higher qualify automatically. The program covers Wegovy, Zepbound, and Foundayo formulations.

Full retail prices reach $1,350 monthly for Wegovy and $1,100 for Zepbound. The $50 copay represents $12,000 annual savings but does not count toward Medicare Part D deductible or the $2,100 out-of-pocket cap.

Clinical Practice Evolution

Dr. Peter Balazs calls for reframing GLP-1 drugs as multi-system metabolic modulators rather than simple weight loss medications. Treatment goals now focus on total cardiometabolic risk reduction across liver, heart, kidneys, and blood vessels.

Salas-Whalen reports patients regularly build muscle while losing body fat when following the GPS protocol. The key is starting strength training and adequate protein intake before beginning GLP-1 therapy.

Read more: The Doctor-Approved Plan for Taking a GLP-1 Without Losing Your Muscle